The Summary
In a 40-week, double-blind randomized controlled trial, researchers evaluated the once-weekly combination drug CagriSema (cagrilintide and semaglutide) in 189 adults with early-stage type 2 diabetes. Participants received CagriSema (2.4 mg or 1.0 mg) or a placebo. The high-dose CagriSema group experienced a dramatic 1.8 percentage point drop in HbA1c, compared to just 0.1 percentage points for placebo. Additionally, CagriSema 2.4 mg led to an outstanding 13.8% reduction in body weight. Mild to moderate gastrointestinal issues were the most common side effects reported.
Why this is interesting
Traditionally, managing early type 2 diabetes relied on single-target medications alongside diet and exercise, which often yielded modest results. CagriSema combines two different gut hormones—amylin and GLP-1 receptor agonists—to hit appetite and blood sugar control from multiple angles. This study proves that dual-action therapies can achieve unprecedented, simultaneous drops in both blood sugar and body weight safely. For patients, this represents a highly effective next-generation therapy that could dramatically simplify their treatment routine while providing powerful, dual-benefit health improvements.